EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY ( ESMO ) : TARLATAMAB APORTA 5,3 MESES MÁS DE OVERALL SURVIVAL ( OS ) en Comparación Con la QUIMIOTERAPIA ( LURBINECTEDIN o AMRUBICIN o TOPOTECAN ) en Pacientes con SMALL CELL LUNG CANCER en el Tratamiento de Segunda Línea .

LO QUE MÁS HA SORPRENDIDO CON TARLATAMAB VERSUS LURBINECTEDIN :

The incidence of adverse events of grade 3 or higher was lower with tarlatamab than with chemotherapy (54% versus 80%), as was the incidence of adverse events resulting in treatment discontinuation (5% versus 12%) .

Treatment with tarlatamab resulted in significantly greater decreases in symptom scores than chemotherapy with respect to dyspnoea and cough .

TRADUCCIÓN :

La incidencia de eventos adversos de grado 3 o superior fue menor con tarlatamab que con quimioterapia (54 % frente a 80 %), al igual que la incidencia de eventos adversos que obligaron a la interrupción del tratamiento (5 % frente a 12 %) .

El tratamiento con tarlatamab produjo reducciones significativamente mayores en las puntuaciones de los síntomas que la quimioterapia con respecto a la disnea y la tos .

A Total Of 509 Patients Were Randomly Assigned To Receive TARLATAMAB ( 254 Patients ) Or Chemotherapy ( 255 Patients ) .

 Treatment With TARLATAMAB Resulted in Significantly Longer OS Than Chemotherapy with a Median OS of 13.6 Months ( 95% confidence interval [CI] 11.1 to Not reached ) Versus 8.3 Months ( 95% CI 7.0 to 10.2 ) and Stratified Hazard Ratio for death of 0.60 (95% CI 0.47 to 0.77; p < 0.001) .

TARLATAMAB Treatment Also Had a Benefit with Respect to PFS with Median of 4.2 Months (95% CI 3.4 to 4.5) in the TARLATAMAB Group and 3.7 Months (95% CI 2.9 to 4.2) in the Chemotherapy Group .

 The Confirmed Objective Response Was 35% in the TARLATAMAB Group as Compared with 20% in the Chemotherapy Group ( risk ratio 1.73; 95% CI 1.29 to 2.33 ) . ...